News

According to the approval, the percentage of study eyes returning to ≤0.2 mm from baseline pupil diameter was statistically significantly greater in the phentolamine ophthalmic solution group than placebo.

Nearly 95% of patients with HCV treated with DAA therapy achieved SVR, regardless of alcohol consumption.

Long-term data from NODE-302 suggests self-administered etripamil nasal spray for rapid heartbeat during PSVT well-tolerated and effective.

The biosimilar was deemed comparable and tolerable in terms of safety between groups.

This segment of Lungcast guest Dr. Barbara Taylor’s discussion covered the topic of new RSV vaccines as well as the spacing of others such as those of COVID-19 and influenza.

Type 1 diabetes was diagnosed later for men than women and for racial and ethnic minority adults than non-Hispanic White adults.

In this interview, Dr. Kim described his response to the FDA’s decision not to approve the intranasal epinephrine spray treatment for anaphylaxis and other severe allergic reactions.

A trio of healthcare providers offer perspective on educating patients regarding biosimilar and interchangeability.

The agency’s guideline updates were announced, with the overall goal being to help food facilities in their adherence to current good manufacturing practices.

Announced by Ionis Pharmaceuticals, topline results show olezarsen met the study's primary endpoint with a statistically significant reduction in triglyceride levels versus placebo.

According to the analysis, high-performing primary care practices use similar strategies to manage change and quality improvement in care for people with diabetes.

Participants indicated multiple factors affected their decision to contact out-of-hours primary care for their child with gastroenteritis and detailed areas of disconnect between their expectations and actions taken by the general practitioner.

In this segment of Lungcast’s September episode, guest Dr. Barbara Taylor talked about the potential for a future universal flu vaccine as well as other potential advancements in the field.

Incidental CAC detection on ASCVD risk assessment revealed differences in prevalence by age, sex, and race and ethnicity.

In Lungcast’s September episode, guest Dr. Barbara Taylor discusses transmission and diagnosis of RSV as well as the possibility of a so-called ‘triple-demic.’

The new educational initiative was launched to provide useful insights from dermatologists as well as personal accounts by patients with seborrheic dermatitis with many different backgrounds.

Data from the phase 2a trial showed 25.7% of patients with UC demonstrated endoscopic improvement and 45.7% achieved clinical response after week 12.

The presence of NAFLD increased from 25.3% to 29.4% among patients receiving oral menopause hormone therapy.

A network meta-analysis suggests tirzepatide may be more effective than semaglutide in reducing HbA1c and body weight in type 2 diabetes but may increase gastrointestinal adverse events, especially at higher doses.

The analysis reports clinical characteristics and the GA progression rate in an Asian population differ from those previously reported in White populations.

New research on the effects of the Canadian wildfires on asthma syndrome in patients sheds light on the downstream effects of ecological disaster on regions outside of those affected.

Results from both studies showed the safety of filgotinib for the treatment of ulcerative colitis compared to placebo treatment groups.

Phase 3 results show the non-inferior efficacy of biosimilar liraglutide to the originator in lowering HbA1C over 26 weeks of treatment.

Smartphone measurements were found to be accurate and precise compared with Hertel exophthalmometry or a high-resolution scanner.

Investigators suggested an ALT/HDL-C ratio of 15.97 as a screening threshold for identifying NAFLD, noting its increased effectiveness compared to ALT, HDL-C, the aspartate aminotransferase to HDL-C ratio, and the gamma-glutamyl transferase to HDL-C ratio.

Eli Lilly and Company and Boehringer Ingelheim announced the FDA approval of empagliflozin (Jardiance) for chronic kidney disease management on September 22, 2023.

Results showed increased liver stiffness measured by vibration-controlled transient elastography was associated with all-cause mortality in patients with NAFLD.

Sarah Wheeler, PharmD, and John Bucheit, PharmD, provide perspective on contemporary trends in screening and management of nonalcoholic fatty liver disease in people with type 2 diabetes.